Zimmer Biomet (ZBH) PT Raised to $132 at Oppenheimer Following 4Q Report
Oppenheimer raised its price target on Zimmer Biomet (NYSE: ZBH) to $132.00 (from $126.00) while maintaining a Outperform rating.Analyst Steven ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)